Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 10/20 | 1.00 |
| ▸ | ELANE | P08246 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | PIM1 | P11309 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.63 |
| ▸ | GMNN | O75496 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | ESR1 | P03372 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38662862 | 1.00 | ACLY (1.00) | ACLYELANEALDH1A1MAPTPIM1 | |
| SCHEMBL2622322 | 0.95 | ACLY (0.91) | ACLYELANEALDH1A1MAPTPIM1 | |
| SCHEMBL30940070 | 0.85 | ACLY (0.73) | ACLYELANEALDH1A1MAPTPIM1 | |
| SCHEMBL12304029 | 0.84 | ELANE (0.85) | ACLYELANEALDH1A1MAPTPIM1 | |
| SCHEMBL10905885 | 0.84 | ACLY (0.72) | ACLYELANEALDH1A1MAPTPIM1 | |
| SCHEMBL29359760 | 0.84 | ACLY (0.72) | ACLYELANEALDH1A1MAPTPIM1 | |
| SCHEMBL23199021 | 0.84 | ACLY (0.72) | ACLYELANEALDH1A1MAPTPIM1 | |
| SCHEMBL27879740 | 0.82 | ACLY (1.00) | ACLYELANEALDH1A1MAPTPIM1 | |
| SCHEMBL27848653 | 0.81 | ACLY (1.00) | ACLYELANEALDH1A1MAPTPIM1 | |
| SCHEMBL27865564 | 0.81 | ACLY (0.70) | ACLYELANEALDH1A1MAPTPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943085-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2022-01-26 | — | — | EP | claimed |
| CN-122031534-A | Application of velvet antler mushroom extract in preparation of medicine for preventing and treating non-alcoholic fatty liver disease | 贵州医科大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-113546067-B | Anthraquinone derivatives with antiviral effect | 四川大学华西医院 | 2023-03-07 | — | — | CN | disclosed |
| EP-3943085-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2022-01-26 | — | — | EP | disclosed |
| CN-113546067-A | Anthraquinone derivatives with antiviral effect | 四川大学华西医院 | 2021-10-26 | — | — | CN | disclosed |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH ZURICH (CH) | 2021-06-24 | — | — | US | disclosed |
| EP-3801507-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2021-04-14 | — | — | EP | disclosed |
| US-20170298209-A1 | USE OF A QUINONE COMPOUND IN BUILDING MATERIALS | ARKION LIFE SCIENCES, LLC (US) | 2017-10-19 | — | — | US | disclosed |
| US-20150208657-A1 | USE OF QUINONE COMPOUND IN BUILDING MATERIALS | ARKION LIFE SCIENCES, LLC (US) | 2015-07-30 | — | — | US | disclosed |
| CN-102775291-A | Emodin derivative and application thereof in preparing antibacterial agents | UNIV SICHUAN | 2012-11-14 | — | — | CN | disclosed |
| WO-2008100977-A2 | CARBAMATES THERAPEUTIC RELEASE AGENTS AS AMIDASE INHIBITORS | N.V. ORGANON (NL) | 2008-08-21 | — | — | WO | disclosed |
| US-20030082101-A1 | Accelerators for increasing the rate of formation of free radicals and reactive oxygen species | CAVALIER DISCOVERY | 2003-05-01 | — | — | US | disclosed |
| WO-2002100478-A9 | ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES | CAVALIER DISCOVERY (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002100478-A2 | ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES | CAVALIER DISCOVERY (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082101-A1 | Accelerators for increasing the rate of formation of free radicals and reactive oxygen species | SOD1, SOD3, APEX1 | ACLY 2279/4885ELANE 1326/4885ALDH1A1 1216/4885 |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | TOMM70, TOMM34, TIMM50 | ACLY 1316/4885ELANE 4808/4885ALDH1A1 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.